Novo Nordisk reported data from the SUSTAIN 4 trial in which semaglutide significantly improved glycemic control vs. insulin glargine U100 in adults with type 2 diabetes. Semaglutide is an investigational glucagon-like peptide-1 (GLP-1) analog. 

SUSTAIN 4 (n=1,089) was a Phase 3, randomized, open-label, multicenter, multinational, 30-week trial evaluating the safety and efficacy of once-weekly semaglutide vs. once-daily insulin glargine (U100/mL), both added to metformin with or without sulfonylurea. 

Related Articles

Data from SUSTAIN 4 showed that study patients achieved statistically significant and superior improvements in HbA1c reductions of 1.2% and 1.6% when treated with 0.5mg and 1mg semaglutide, respectively vs. a 0.8% reduction with insulin glargine U100 (P<0.0001 for both). A greater percent of  adults treated with semaglutide 0.5mg and 1mg met HbA1c targets vs. adults treated with insulin glargine: HbA1c <7% (57.5% and 73.3% vs. 38.1%) and HbA1c ≤6.5% (37.3% and 54.2% vs. 17.5%)

Continue Reading

Also, adults treated with semaglutide achieved statistically significant and superior reductions in mean body weight of 3.5kg and 5.2kg vs. an increase of 1.2kg seen with the insulin glargine-treated patients (P<0.0001 for both). 

The rate of serious adverse events were similar across the treatment groups (6.1% and 4.7% vs. 5.0%). 

For more information call (800) 727-6500 or visit